The aim of the study was to determine if doxycycline causes tooth staining in young children. A dentist examined 31 randomized children who had been treated with doxycycline and 30 children who had not received doxycycline. Mean age of the children was 10.4 ∓ 2.1 years. Mean age at receipt of the first doxycycline treatment was 4.1 ∓ 1.6 years, and mean number of doxycycline courses was 2.0 ∓ 1.3. No tooth staining was detected by the dentist in any of the children in either group. These findings indicate that treatment with doxycycline in children aged 2 to 8 years is not associated with tooth staining.
Gupta SK, Sarosi GA.The role of atypical pathogens in community-acquired pneumonia. Med Clin North Am.2001;85: 1349-1365.
2.
Thibodeau KP, Viera AJ.Atypical pathogens and challenges in community-acquired pneumonia. Am Fam Physician.2004;69: 1699-1706.
3.
Thumerelle C, Deschildre A, Bouquillon C, et al.Role of viruses and atypical bacteria in exacerbations of asthma in hospitalized children: a prospective study in the Nord-Pas de Calais region (France). Pediatr Pulmonol.2003;35: 75-82.
4.
Ouchi K, Komura H, Fujii M, et al.Chlamydia pneumoniae infection and Mycoplasma pneumoniae infection in pediatric patients. Kansenshogaku Zasshi. 1999;73: 1177-1182.
5.
Biscardi S, Lorrot M, Marc E, et al.Mycoplasma pneumoniae and asthma in children. Clin Infect Dis.2004; 38: 1341-1346.
6.
Esposito S, Principi N.Asthma in children: are chlamydia or mycoplasma involved? Paediatr Drugs.2001;3: 159-168.
7.
Abramson JS, Givner LB.Should tetracycline be contraindicated for therapy of presumed Rocky Mountain spotted fever in children less than 9 years of age? Pediatrics.1990; 86: 123-124.
8.
Liu C.Mycoplasma pneumonia. In: Hoeprich PD, Jordan MC, Ronald AR, eds. Infectious Diseases: A Treatise of Infectious Processes. 5th ed.Philadelphia, Penn: Lippincott; 1994:411-416.
9.
Principi N, Esposito S, Blasi F, et al.Role of Mycoplasma pneumoniae and Chlamydia pneumoniae in children with community-acquired lower respiratory tract infections. Clin Infect Dis.2001;32: 1281-1289.
10.
Block S, Hedrick J, Hammerschlag MR, et al.Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia: comparative efficacy and safety of clarithromycin vs. erythromycin ethylsuccinate. Pediatr Infect Dis J.1995;14: 471-477.
11.
Marrie TJ, Peeling RW, Fine MJ, et al.Ambulatory patients with community-acquired pneumonia: the frequency of atypical agents and clinical course. Am J Med.1996;101: 508-515.
12.
Harris JA, Kolokathis A, Campbell M, et al.Safety and efficacy of azithromycin in the treatment of community-acquired pneumonia in children. Pediatr Infect Dis J.1998;17: 865-871.
13.
Daian CM, Wolff AH, Bielory L.The role of atypical organisms in asthma. Allergy Asthma Proc.2000;21: 107-111.
14.
Wallman IS, Hilton HB.Teeth pigmented by tetracycline. Lancet.1962;1: 827-829.
15.
Shwachman H, Feket E, Kulczycki L, et al.The effect of long-term antibiotic therapy in a patient with cystic fibrosis of the pancreas. Antibiotics Annual.1958;59: 692-699.
16.
Porter PJ, Sweeney EA, Golan H, et al.Controlled study of the effect of prenatal tetracycline on primary dentition. Antimicrobial Agents Chemother. 965;5: 668-671.
17.
Department of Health Education and Welfare. Tetracycline pediatric drops to be withdrawn from market. FDA Bull.1978;8: 23-23.
18.
American Academy of Pediatrics. Rocky Mountain spotted fever. In: Pickering L, ed. 2000 Red Book: Report of the committee on infectious diseases. 25th ed.Elk Grove Village, Ill: American Academy of Pediatrics; 2000:646-646.
19.
Committee of Infectious Diseases. Rocky Mountain Spotted Fever. Elk Grove Village, Ill: American Academy of Pediatrics; 1991:405-407.
20.
Lochary ME, Lockhart PB, Williams WT Jr.Doxycycline and staining of permanent teeth. Pediatr Infect Dis J.1998;17: 429-431.
21.
Cale DF, McCarthy MW.Treatment of Rocky Mountain spotted fever in children. Ann Pharmacother.1997;31: 492-494.
22.
Forti G, Benincori C.Doxycycline and the teeth. Letter to the Editor. Lancet.1969; 1: 782-782.
23.
Hasegawa A, Ikeda I, Kawaguchi S.Color and translucency of in vivo natural central incisors. J Prosthet Dent.2000;83: 418-423
24.
Shetty AK.Tetracyclines in pediatrics revised. Clin Pediatr.2002;41: 203-209.
25.
Grossman ER, Walchek A, Freedman H.Tetracyclines and permanent teeth: the relation between dose and tooth color. Pediatrics.1971;47: 567-570.
26.
Stewart RE, Barber TK, Troutman KC, Wei SHY, eds. Pediatric Dentistry. 7th ed.St Louis, Mo: Mosby; 2000.
27.
Ragnar Norrby S.Atypical pneumonia in the Nordic countries: aetiology and clinical results of a trial comparing fleroxacin and doxycycline. Nordic Atypical Pneumonia Study Group. J Antimicrob Chemother.1997;39: 499-508.
28.
Freymuth F, Vabret A, Brouard J, et al.Detection of viral, Chlamydia pneumoniae and Mycoplasma pneumoniae infections in exacerbations of asthma in children. J Clin Virol.1999;13: 131-139.
29.
Esposito S, Blasi F, Arosio C, et al.Importance of acute Mycoplasma pneumoniae and Chlamydia pneumoniae infections in children with wheezing. Eur Respir J.2000;16: 1142-1146.
30.
Principi N, Esposito S.Emerging role of Mycoplasma pneumoniae and Chlamydia pneumoniae in paediatric respiratory-tract infections. Lancet Infect Dis.2001;1: 334-344.
31.
Principi N, Esposito S.Mycoplasma pneumoniae and Chlamydia pneumoniae cause lower respiratory tract disease in paediatric patients. Curr Opin Infect Dis.2002;15: 295-300.
32.
Nelson CT.Mycoplasma and Chlamydia pneumonia in pediatrics. Semin Respir Infect.2002;17: 10-14.
